Global Furmonertinib Mesylate Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Furmonertinib Mesylate market size was valued at US$ 971 million in 2025 and is forecast to a readjusted size of US$ 1934 million by 2032 with a CAGR of 11.6% during review period.
In 2025, global Furmonertinib Mesylate Tablets production reached approximately 380,000 units.Furmonertinib Mesylate is an oral third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), primarily used for the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations or the T790M resistance mutation. It works by selectively and irreversibly inhibiting the kinase activity of mutant EGFR, thereby blocking tumor cell proliferation and survival signaling pathways and suppressing tumor growth. Furmonertinib mesylate is characterized by high selectivity for mutant EGFR, good central nervous system penetration, and a relatively manageable safety profile, making it clinically valuable in the treatment of advanced non-small cell lung cancer.
Furmonertinib Mesylate, as a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), operates in a rapidly developing and highly competitive segment of the non-small cell lung cancer (NSCLC) targeted therapy market, particularly demonstrating strong competitiveness in patients with EGFR mutations and T790M resistance mutations. With the large population of lung cancer patients and the continuous improvement in the penetration of genetic testing, the demand for precision medicine is steadily increasing, providing a solid market foundation for this class of drugs.
From a competitive landscape perspective, imported originator drugs represented by Osimertinib have long dominated the market. However, furmonertinib mesylate, leveraging its domestic R&D advantages, price competitiveness, and potential efficacy in patients with central nervous system metastases, is gradually gaining market share in China.
On the policy side, its inclusion in the national reimbursement drug list helps improve patient accessibility and promote market expansion, although healthcare cost-control measures and volume-based procurement policies continue to exert pressure on pricing. From a competitive standpoint, multiple third-generation EGFR-TKIs and next-generation targeted therapies from both domestic and international companies are continuously entering the market. In addition, the development of immunotherapy combination regimens is further intensifying competition. Therefore, the future market performance of furmonertinib mesylate will depend on its penetration in first-line treatment, expansion of indications (such as adjuvant therapy or additional mutation subtypes), and the accumulation of real-world evidence, as well as its overall competitive balance in terms of efficacy, safety, and pricing.
This report is a detailed and comprehensive analysis for global Furmonertinib Mesylate market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Furmonertinib Mesylate market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Furmonertinib Mesylate market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Furmonertinib Mesylate market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Furmonertinib Mesylate market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Furmonertinib Mesylate market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Furmonertinib Mesylate product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Furmonertinib Mesylate, with price, sales quantity, revenue, and global market share of Furmonertinib Mesylate from 2021 to 2026.
Chapter 3, the Furmonertinib Mesylate competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Furmonertinib Mesylate breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Furmonertinib Mesylate market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Furmonertinib Mesylate.
Chapter 14 and 15, to describe Furmonertinib Mesylate sales channel, distributors, customers, research findings and conclusion.
In 2025, global Furmonertinib Mesylate Tablets production reached approximately 380,000 units.Furmonertinib Mesylate is an oral third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), primarily used for the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations or the T790M resistance mutation. It works by selectively and irreversibly inhibiting the kinase activity of mutant EGFR, thereby blocking tumor cell proliferation and survival signaling pathways and suppressing tumor growth. Furmonertinib mesylate is characterized by high selectivity for mutant EGFR, good central nervous system penetration, and a relatively manageable safety profile, making it clinically valuable in the treatment of advanced non-small cell lung cancer.
Furmonertinib Mesylate, as a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), operates in a rapidly developing and highly competitive segment of the non-small cell lung cancer (NSCLC) targeted therapy market, particularly demonstrating strong competitiveness in patients with EGFR mutations and T790M resistance mutations. With the large population of lung cancer patients and the continuous improvement in the penetration of genetic testing, the demand for precision medicine is steadily increasing, providing a solid market foundation for this class of drugs.
From a competitive landscape perspective, imported originator drugs represented by Osimertinib have long dominated the market. However, furmonertinib mesylate, leveraging its domestic R&D advantages, price competitiveness, and potential efficacy in patients with central nervous system metastases, is gradually gaining market share in China.
On the policy side, its inclusion in the national reimbursement drug list helps improve patient accessibility and promote market expansion, although healthcare cost-control measures and volume-based procurement policies continue to exert pressure on pricing. From a competitive standpoint, multiple third-generation EGFR-TKIs and next-generation targeted therapies from both domestic and international companies are continuously entering the market. In addition, the development of immunotherapy combination regimens is further intensifying competition. Therefore, the future market performance of furmonertinib mesylate will depend on its penetration in first-line treatment, expansion of indications (such as adjuvant therapy or additional mutation subtypes), and the accumulation of real-world evidence, as well as its overall competitive balance in terms of efficacy, safety, and pricing.
This report is a detailed and comprehensive analysis for global Furmonertinib Mesylate market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Furmonertinib Mesylate market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Furmonertinib Mesylate market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Furmonertinib Mesylate market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Furmonertinib Mesylate market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Furmonertinib Mesylate
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Furmonertinib Mesylate market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- 40 mg
- 80 mg
- Hospital
- Retail
- Online
- Non-small Cell Lung Cancer (NSCLC) Treatment
- Patients With Central Nervous System Metastases
- First-line and Later-line Targeted Therapy
- Others
- Allist Pharmaceuticals
- Jiangsu Allist Biopharmaceutical
- TargetMol
- MedChemExpress
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Furmonertinib Mesylate product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Furmonertinib Mesylate, with price, sales quantity, revenue, and global market share of Furmonertinib Mesylate from 2021 to 2026.
Chapter 3, the Furmonertinib Mesylate competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Furmonertinib Mesylate breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Furmonertinib Mesylate market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Furmonertinib Mesylate.
Chapter 14 and 15, to describe Furmonertinib Mesylate sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Furmonertinib Mesylate Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 40 mg
1.3.3 80 mg
1.4 Market Analysis by Sales Channels
1.4.1 Overview: Global Furmonertinib Mesylate Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
1.4.2 Hospital
1.4.3 Retail
1.4.4 Online
1.5 Market Analysis by Application
1.5.1 Overview: Global Furmonertinib Mesylate Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.5.2 Non-small Cell Lung Cancer (NSCLC) Treatment
1.5.3 Patients With Central Nervous System Metastases
1.5.4 First-line and Later-line Targeted Therapy
1.5.5 Others
1.6 Global Furmonertinib Mesylate Market Size & Forecast
1.6.1 Global Furmonertinib Mesylate Consumption Value (2021 & 2025 & 2032)
1.6.2 Global Furmonertinib Mesylate Sales Quantity (2021-2032)
1.6.3 Global Furmonertinib Mesylate Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Allist Pharmaceuticals
2.1.1 Allist Pharmaceuticals Details
2.1.2 Allist Pharmaceuticals Major Business
2.1.3 Allist Pharmaceuticals Furmonertinib Mesylate Product and Services
2.1.4 Allist Pharmaceuticals Furmonertinib Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Allist Pharmaceuticals Recent Developments/Updates
2.2 Jiangsu Allist Biopharmaceutical
2.2.1 Jiangsu Allist Biopharmaceutical Details
2.2.2 Jiangsu Allist Biopharmaceutical Major Business
2.2.3 Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Product and Services
2.2.4 Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Jiangsu Allist Biopharmaceutical Recent Developments/Updates
2.3 TargetMol
2.3.1 TargetMol Details
2.3.2 TargetMol Major Business
2.3.3 TargetMol Furmonertinib Mesylate Product and Services
2.3.4 TargetMol Furmonertinib Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 TargetMol Recent Developments/Updates
2.4 MedChemExpress
2.4.1 MedChemExpress Details
2.4.2 MedChemExpress Major Business
2.4.3 MedChemExpress Furmonertinib Mesylate Product and Services
2.4.4 MedChemExpress Furmonertinib Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 MedChemExpress Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: FURMONERTINIB MESYLATE BY MANUFACTURER
3.1 Global Furmonertinib Mesylate Sales Quantity by Manufacturer (2021-2026)
3.2 Global Furmonertinib Mesylate Revenue by Manufacturer (2021-2026)
3.3 Global Furmonertinib Mesylate Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Furmonertinib Mesylate by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Furmonertinib Mesylate Manufacturer Market Share in 2025
3.4.3 Top 6 Furmonertinib Mesylate Manufacturer Market Share in 2025
3.5 Furmonertinib Mesylate Market: Overall Company Footprint Analysis
3.5.1 Furmonertinib Mesylate Market: Region Footprint
3.5.2 Furmonertinib Mesylate Market: Company Product Type Footprint
3.5.3 Furmonertinib Mesylate Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Furmonertinib Mesylate Market Size by Region
4.1.1 Global Furmonertinib Mesylate Sales Quantity by Region (2021-2032)
4.1.2 Global Furmonertinib Mesylate Consumption Value by Region (2021-2032)
4.1.3 Global Furmonertinib Mesylate Average Price by Region (2021-2032)
4.2 North America Furmonertinib Mesylate Consumption Value (2021-2032)
4.3 Europe Furmonertinib Mesylate Consumption Value (2021-2032)
4.4 Asia-Pacific Furmonertinib Mesylate Consumption Value (2021-2032)
4.5 South America Furmonertinib Mesylate Consumption Value (2021-2032)
4.6 Middle East & Africa Furmonertinib Mesylate Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Furmonertinib Mesylate Sales Quantity by Type (2021-2032)
5.2 Global Furmonertinib Mesylate Consumption Value by Type (2021-2032)
5.3 Global Furmonertinib Mesylate Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Furmonertinib Mesylate Sales Quantity by Application (2021-2032)
6.2 Global Furmonertinib Mesylate Consumption Value by Application (2021-2032)
6.3 Global Furmonertinib Mesylate Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Furmonertinib Mesylate Sales Quantity by Type (2021-2032)
7.2 North America Furmonertinib Mesylate Sales Quantity by Application (2021-2032)
7.3 North America Furmonertinib Mesylate Market Size by Country
7.3.1 North America Furmonertinib Mesylate Sales Quantity by Country (2021-2032)
7.3.2 North America Furmonertinib Mesylate Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Furmonertinib Mesylate Sales Quantity by Type (2021-2032)
8.2 Europe Furmonertinib Mesylate Sales Quantity by Application (2021-2032)
8.3 Europe Furmonertinib Mesylate Market Size by Country
8.3.1 Europe Furmonertinib Mesylate Sales Quantity by Country (2021-2032)
8.3.2 Europe Furmonertinib Mesylate Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Furmonertinib Mesylate Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Furmonertinib Mesylate Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Furmonertinib Mesylate Market Size by Region
9.3.1 Asia-Pacific Furmonertinib Mesylate Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Furmonertinib Mesylate Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Furmonertinib Mesylate Sales Quantity by Type (2021-2032)
10.2 South America Furmonertinib Mesylate Sales Quantity by Application (2021-2032)
10.3 South America Furmonertinib Mesylate Market Size by Country
10.3.1 South America Furmonertinib Mesylate Sales Quantity by Country (2021-2032)
10.3.2 South America Furmonertinib Mesylate Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Furmonertinib Mesylate Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Furmonertinib Mesylate Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Furmonertinib Mesylate Market Size by Country
11.3.1 Middle East & Africa Furmonertinib Mesylate Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Furmonertinib Mesylate Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Furmonertinib Mesylate Market Drivers
12.2 Furmonertinib Mesylate Market Restraints
12.3 Furmonertinib Mesylate Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Furmonertinib Mesylate and Key Manufacturers
13.2 Manufacturing Costs Percentage of Furmonertinib Mesylate
13.3 Furmonertinib Mesylate Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Furmonertinib Mesylate Typical Distributors
14.3 Furmonertinib Mesylate Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Furmonertinib Mesylate Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 40 mg
1.3.3 80 mg
1.4 Market Analysis by Sales Channels
1.4.1 Overview: Global Furmonertinib Mesylate Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
1.4.2 Hospital
1.4.3 Retail
1.4.4 Online
1.5 Market Analysis by Application
1.5.1 Overview: Global Furmonertinib Mesylate Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.5.2 Non-small Cell Lung Cancer (NSCLC) Treatment
1.5.3 Patients With Central Nervous System Metastases
1.5.4 First-line and Later-line Targeted Therapy
1.5.5 Others
1.6 Global Furmonertinib Mesylate Market Size & Forecast
1.6.1 Global Furmonertinib Mesylate Consumption Value (2021 & 2025 & 2032)
1.6.2 Global Furmonertinib Mesylate Sales Quantity (2021-2032)
1.6.3 Global Furmonertinib Mesylate Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Allist Pharmaceuticals
2.1.1 Allist Pharmaceuticals Details
2.1.2 Allist Pharmaceuticals Major Business
2.1.3 Allist Pharmaceuticals Furmonertinib Mesylate Product and Services
2.1.4 Allist Pharmaceuticals Furmonertinib Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Allist Pharmaceuticals Recent Developments/Updates
2.2 Jiangsu Allist Biopharmaceutical
2.2.1 Jiangsu Allist Biopharmaceutical Details
2.2.2 Jiangsu Allist Biopharmaceutical Major Business
2.2.3 Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Product and Services
2.2.4 Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Jiangsu Allist Biopharmaceutical Recent Developments/Updates
2.3 TargetMol
2.3.1 TargetMol Details
2.3.2 TargetMol Major Business
2.3.3 TargetMol Furmonertinib Mesylate Product and Services
2.3.4 TargetMol Furmonertinib Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 TargetMol Recent Developments/Updates
2.4 MedChemExpress
2.4.1 MedChemExpress Details
2.4.2 MedChemExpress Major Business
2.4.3 MedChemExpress Furmonertinib Mesylate Product and Services
2.4.4 MedChemExpress Furmonertinib Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 MedChemExpress Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: FURMONERTINIB MESYLATE BY MANUFACTURER
3.1 Global Furmonertinib Mesylate Sales Quantity by Manufacturer (2021-2026)
3.2 Global Furmonertinib Mesylate Revenue by Manufacturer (2021-2026)
3.3 Global Furmonertinib Mesylate Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Furmonertinib Mesylate by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Furmonertinib Mesylate Manufacturer Market Share in 2025
3.4.3 Top 6 Furmonertinib Mesylate Manufacturer Market Share in 2025
3.5 Furmonertinib Mesylate Market: Overall Company Footprint Analysis
3.5.1 Furmonertinib Mesylate Market: Region Footprint
3.5.2 Furmonertinib Mesylate Market: Company Product Type Footprint
3.5.3 Furmonertinib Mesylate Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Furmonertinib Mesylate Market Size by Region
4.1.1 Global Furmonertinib Mesylate Sales Quantity by Region (2021-2032)
4.1.2 Global Furmonertinib Mesylate Consumption Value by Region (2021-2032)
4.1.3 Global Furmonertinib Mesylate Average Price by Region (2021-2032)
4.2 North America Furmonertinib Mesylate Consumption Value (2021-2032)
4.3 Europe Furmonertinib Mesylate Consumption Value (2021-2032)
4.4 Asia-Pacific Furmonertinib Mesylate Consumption Value (2021-2032)
4.5 South America Furmonertinib Mesylate Consumption Value (2021-2032)
4.6 Middle East & Africa Furmonertinib Mesylate Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Furmonertinib Mesylate Sales Quantity by Type (2021-2032)
5.2 Global Furmonertinib Mesylate Consumption Value by Type (2021-2032)
5.3 Global Furmonertinib Mesylate Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Furmonertinib Mesylate Sales Quantity by Application (2021-2032)
6.2 Global Furmonertinib Mesylate Consumption Value by Application (2021-2032)
6.3 Global Furmonertinib Mesylate Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Furmonertinib Mesylate Sales Quantity by Type (2021-2032)
7.2 North America Furmonertinib Mesylate Sales Quantity by Application (2021-2032)
7.3 North America Furmonertinib Mesylate Market Size by Country
7.3.1 North America Furmonertinib Mesylate Sales Quantity by Country (2021-2032)
7.3.2 North America Furmonertinib Mesylate Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Furmonertinib Mesylate Sales Quantity by Type (2021-2032)
8.2 Europe Furmonertinib Mesylate Sales Quantity by Application (2021-2032)
8.3 Europe Furmonertinib Mesylate Market Size by Country
8.3.1 Europe Furmonertinib Mesylate Sales Quantity by Country (2021-2032)
8.3.2 Europe Furmonertinib Mesylate Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Furmonertinib Mesylate Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Furmonertinib Mesylate Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Furmonertinib Mesylate Market Size by Region
9.3.1 Asia-Pacific Furmonertinib Mesylate Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Furmonertinib Mesylate Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Furmonertinib Mesylate Sales Quantity by Type (2021-2032)
10.2 South America Furmonertinib Mesylate Sales Quantity by Application (2021-2032)
10.3 South America Furmonertinib Mesylate Market Size by Country
10.3.1 South America Furmonertinib Mesylate Sales Quantity by Country (2021-2032)
10.3.2 South America Furmonertinib Mesylate Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Furmonertinib Mesylate Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Furmonertinib Mesylate Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Furmonertinib Mesylate Market Size by Country
11.3.1 Middle East & Africa Furmonertinib Mesylate Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Furmonertinib Mesylate Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Furmonertinib Mesylate Market Drivers
12.2 Furmonertinib Mesylate Market Restraints
12.3 Furmonertinib Mesylate Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Furmonertinib Mesylate and Key Manufacturers
13.2 Manufacturing Costs Percentage of Furmonertinib Mesylate
13.3 Furmonertinib Mesylate Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Furmonertinib Mesylate Typical Distributors
14.3 Furmonertinib Mesylate Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Furmonertinib Mesylate Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Furmonertinib Mesylate Consumption Value by Sales Channels, (USD Million), 2021 & 2025 & 2032
Table 3. Global Furmonertinib Mesylate Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 4. Allist Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 5. Allist Pharmaceuticals Major Business
Table 6. Allist Pharmaceuticals Furmonertinib Mesylate Product and Services
Table 7. Allist Pharmaceuticals Furmonertinib Mesylate Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 8. Allist Pharmaceuticals Recent Developments/Updates
Table 9. Jiangsu Allist Biopharmaceutical Basic Information, Manufacturing Base and Competitors
Table 10. Jiangsu Allist Biopharmaceutical Major Business
Table 11. Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Product and Services
Table 12. Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 13. Jiangsu Allist Biopharmaceutical Recent Developments/Updates
Table 14. TargetMol Basic Information, Manufacturing Base and Competitors
Table 15. TargetMol Major Business
Table 16. TargetMol Furmonertinib Mesylate Product and Services
Table 17. TargetMol Furmonertinib Mesylate Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 18. TargetMol Recent Developments/Updates
Table 19. MedChemExpress Basic Information, Manufacturing Base and Competitors
Table 20. MedChemExpress Major Business
Table 21. MedChemExpress Furmonertinib Mesylate Product and Services
Table 22. MedChemExpress Furmonertinib Mesylate Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 23. MedChemExpress Recent Developments/Updates
Table 24. Global Furmonertinib Mesylate Sales Quantity by Manufacturer (2021-2026) & (Units)
Table 25. Global Furmonertinib Mesylate Revenue by Manufacturer (2021-2026) & (USD Million)
Table 26. Global Furmonertinib Mesylate Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 27. Market Position of Manufacturers in Furmonertinib Mesylate, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 28. Head Office and Furmonertinib Mesylate Production Site of Key Manufacturer
Table 29. Furmonertinib Mesylate Market: Company Product Type Footprint
Table 30. Furmonertinib Mesylate Market: Company Product Application Footprint
Table 31. Furmonertinib Mesylate New Market Entrants and Barriers to Market Entry
Table 32. Furmonertinib Mesylate Mergers, Acquisition, Agreements, and Collaborations
Table 33. Global Furmonertinib Mesylate Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 34. Global Furmonertinib Mesylate Sales Quantity by Region (2021-2026) & (Units)
Table 35. Global Furmonertinib Mesylate Sales Quantity by Region (2027-2032) & (Units)
Table 36. Global Furmonertinib Mesylate Consumption Value by Region (2021-2026) & (USD Million)
Table 37. Global Furmonertinib Mesylate Consumption Value by Region (2027-2032) & (USD Million)
Table 38. Global Furmonertinib Mesylate Average Price by Region (2021-2026) & (US$/Unit)
Table 39. Global Furmonertinib Mesylate Average Price by Region (2027-2032) & (US$/Unit)
Table 40. Global Furmonertinib Mesylate Sales Quantity by Type (2021-2026) & (Units)
Table 41. Global Furmonertinib Mesylate Sales Quantity by Type (2027-2032) & (Units)
Table 42. Global Furmonertinib Mesylate Consumption Value by Type (2021-2026) & (USD Million)
Table 43. Global Furmonertinib Mesylate Consumption Value by Type (2027-2032) & (USD Million)
Table 44. Global Furmonertinib Mesylate Average Price by Type (2021-2026) & (US$/Unit)
Table 45. Global Furmonertinib Mesylate Average Price by Type (2027-2032) & (US$/Unit)
Table 46. Global Furmonertinib Mesylate Sales Quantity by Application (2021-2026) & (Units)
Table 47. Global Furmonertinib Mesylate Sales Quantity by Application (2027-2032) & (Units)
Table 48. Global Furmonertinib Mesylate Consumption Value by Application (2021-2026) & (USD Million)
Table 49. Global Furmonertinib Mesylate Consumption Value by Application (2027-2032) & (USD Million)
Table 50. Global Furmonertinib Mesylate Average Price by Application (2021-2026) & (US$/Unit)
Table 51. Global Furmonertinib Mesylate Average Price by Application (2027-2032) & (US$/Unit)
Table 52. North America Furmonertinib Mesylate Sales Quantity by Type (2021-2026) & (Units)
Table 53. North America Furmonertinib Mesylate Sales Quantity by Type (2027-2032) & (Units)
Table 54. North America Furmonertinib Mesylate Sales Quantity by Application (2021-2026) & (Units)
Table 55. North America Furmonertinib Mesylate Sales Quantity by Application (2027-2032) & (Units)
Table 56. North America Furmonertinib Mesylate Sales Quantity by Country (2021-2026) & (Units)
Table 57. North America Furmonertinib Mesylate Sales Quantity by Country (2027-2032) & (Units)
Table 58. North America Furmonertinib Mesylate Consumption Value by Country (2021-2026) & (USD Million)
Table 59. North America Furmonertinib Mesylate Consumption Value by Country (2027-2032) & (USD Million)
Table 60. Europe Furmonertinib Mesylate Sales Quantity by Type (2021-2026) & (Units)
Table 61. Europe Furmonertinib Mesylate Sales Quantity by Type (2027-2032) & (Units)
Table 62. Europe Furmonertinib Mesylate Sales Quantity by Application (2021-2026) & (Units)
Table 63. Europe Furmonertinib Mesylate Sales Quantity by Application (2027-2032) & (Units)
Table 64. Europe Furmonertinib Mesylate Sales Quantity by Country (2021-2026) & (Units)
Table 65. Europe Furmonertinib Mesylate Sales Quantity by Country (2027-2032) & (Units)
Table 66. Europe Furmonertinib Mesylate Consumption Value by Country (2021-2026) & (USD Million)
Table 67. Europe Furmonertinib Mesylate Consumption Value by Country (2027-2032) & (USD Million)
Table 68. Asia-Pacific Furmonertinib Mesylate Sales Quantity by Type (2021-2026) & (Units)
Table 69. Asia-Pacific Furmonertinib Mesylate Sales Quantity by Type (2027-2032) & (Units)
Table 70. Asia-Pacific Furmonertinib Mesylate Sales Quantity by Application (2021-2026) & (Units)
Table 71. Asia-Pacific Furmonertinib Mesylate Sales Quantity by Application (2027-2032) & (Units)
Table 72. Asia-Pacific Furmonertinib Mesylate Sales Quantity by Region (2021-2026) & (Units)
Table 73. Asia-Pacific Furmonertinib Mesylate Sales Quantity by Region (2027-2032) & (Units)
Table 74. Asia-Pacific Furmonertinib Mesylate Consumption Value by Region (2021-2026) & (USD Million)
Table 75. Asia-Pacific Furmonertinib Mesylate Consumption Value by Region (2027-2032) & (USD Million)
Table 76. South America Furmonertinib Mesylate Sales Quantity by Type (2021-2026) & (Units)
Table 77. South America Furmonertinib Mesylate Sales Quantity by Type (2027-2032) & (Units)
Table 78. South America Furmonertinib Mesylate Sales Quantity by Application (2021-2026) & (Units)
Table 79. South America Furmonertinib Mesylate Sales Quantity by Application (2027-2032) & (Units)
Table 80. South America Furmonertinib Mesylate Sales Quantity by Country (2021-2026) & (Units)
Table 81. South America Furmonertinib Mesylate Sales Quantity by Country (2027-2032) & (Units)
Table 82. South America Furmonertinib Mesylate Consumption Value by Country (2021-2026) & (USD Million)
Table 83. South America Furmonertinib Mesylate Consumption Value by Country (2027-2032) & (USD Million)
Table 84. Middle East & Africa Furmonertinib Mesylate Sales Quantity by Type (2021-2026) & (Units)
Table 85. Middle East & Africa Furmonertinib Mesylate Sales Quantity by Type (2027-2032) & (Units)
Table 86. Middle East & Africa Furmonertinib Mesylate Sales Quantity by Application (2021-2026) & (Units)
Table 87. Middle East & Africa Furmonertinib Mesylate Sales Quantity by Application (2027-2032) & (Units)
Table 88. Middle East & Africa Furmonertinib Mesylate Sales Quantity by Country (2021-2026) & (Units)
Table 89. Middle East & Africa Furmonertinib Mesylate Sales Quantity by Country (2027-2032) & (Units)
Table 90. Middle East & Africa Furmonertinib Mesylate Consumption Value by Country (2021-2026) & (USD Million)
Table 91. Middle East & Africa Furmonertinib Mesylate Consumption Value by Country (2027-2032) & (USD Million)
Table 92. Furmonertinib Mesylate Raw Material
Table 93. Key Manufacturers of Furmonertinib Mesylate Raw Materials
Table 94. Furmonertinib Mesylate Typical Distributors
Table 95. Furmonertinib Mesylate Typical Customers
Table 1. Global Furmonertinib Mesylate Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Furmonertinib Mesylate Consumption Value by Sales Channels, (USD Million), 2021 & 2025 & 2032
Table 3. Global Furmonertinib Mesylate Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 4. Allist Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 5. Allist Pharmaceuticals Major Business
Table 6. Allist Pharmaceuticals Furmonertinib Mesylate Product and Services
Table 7. Allist Pharmaceuticals Furmonertinib Mesylate Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 8. Allist Pharmaceuticals Recent Developments/Updates
Table 9. Jiangsu Allist Biopharmaceutical Basic Information, Manufacturing Base and Competitors
Table 10. Jiangsu Allist Biopharmaceutical Major Business
Table 11. Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Product and Services
Table 12. Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 13. Jiangsu Allist Biopharmaceutical Recent Developments/Updates
Table 14. TargetMol Basic Information, Manufacturing Base and Competitors
Table 15. TargetMol Major Business
Table 16. TargetMol Furmonertinib Mesylate Product and Services
Table 17. TargetMol Furmonertinib Mesylate Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 18. TargetMol Recent Developments/Updates
Table 19. MedChemExpress Basic Information, Manufacturing Base and Competitors
Table 20. MedChemExpress Major Business
Table 21. MedChemExpress Furmonertinib Mesylate Product and Services
Table 22. MedChemExpress Furmonertinib Mesylate Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 23. MedChemExpress Recent Developments/Updates
Table 24. Global Furmonertinib Mesylate Sales Quantity by Manufacturer (2021-2026) & (Units)
Table 25. Global Furmonertinib Mesylate Revenue by Manufacturer (2021-2026) & (USD Million)
Table 26. Global Furmonertinib Mesylate Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 27. Market Position of Manufacturers in Furmonertinib Mesylate, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 28. Head Office and Furmonertinib Mesylate Production Site of Key Manufacturer
Table 29. Furmonertinib Mesylate Market: Company Product Type Footprint
Table 30. Furmonertinib Mesylate Market: Company Product Application Footprint
Table 31. Furmonertinib Mesylate New Market Entrants and Barriers to Market Entry
Table 32. Furmonertinib Mesylate Mergers, Acquisition, Agreements, and Collaborations
Table 33. Global Furmonertinib Mesylate Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 34. Global Furmonertinib Mesylate Sales Quantity by Region (2021-2026) & (Units)
Table 35. Global Furmonertinib Mesylate Sales Quantity by Region (2027-2032) & (Units)
Table 36. Global Furmonertinib Mesylate Consumption Value by Region (2021-2026) & (USD Million)
Table 37. Global Furmonertinib Mesylate Consumption Value by Region (2027-2032) & (USD Million)
Table 38. Global Furmonertinib Mesylate Average Price by Region (2021-2026) & (US$/Unit)
Table 39. Global Furmonertinib Mesylate Average Price by Region (2027-2032) & (US$/Unit)
Table 40. Global Furmonertinib Mesylate Sales Quantity by Type (2021-2026) & (Units)
Table 41. Global Furmonertinib Mesylate Sales Quantity by Type (2027-2032) & (Units)
Table 42. Global Furmonertinib Mesylate Consumption Value by Type (2021-2026) & (USD Million)
Table 43. Global Furmonertinib Mesylate Consumption Value by Type (2027-2032) & (USD Million)
Table 44. Global Furmonertinib Mesylate Average Price by Type (2021-2026) & (US$/Unit)
Table 45. Global Furmonertinib Mesylate Average Price by Type (2027-2032) & (US$/Unit)
Table 46. Global Furmonertinib Mesylate Sales Quantity by Application (2021-2026) & (Units)
Table 47. Global Furmonertinib Mesylate Sales Quantity by Application (2027-2032) & (Units)
Table 48. Global Furmonertinib Mesylate Consumption Value by Application (2021-2026) & (USD Million)
Table 49. Global Furmonertinib Mesylate Consumption Value by Application (2027-2032) & (USD Million)
Table 50. Global Furmonertinib Mesylate Average Price by Application (2021-2026) & (US$/Unit)
Table 51. Global Furmonertinib Mesylate Average Price by Application (2027-2032) & (US$/Unit)
Table 52. North America Furmonertinib Mesylate Sales Quantity by Type (2021-2026) & (Units)
Table 53. North America Furmonertinib Mesylate Sales Quantity by Type (2027-2032) & (Units)
Table 54. North America Furmonertinib Mesylate Sales Quantity by Application (2021-2026) & (Units)
Table 55. North America Furmonertinib Mesylate Sales Quantity by Application (2027-2032) & (Units)
Table 56. North America Furmonertinib Mesylate Sales Quantity by Country (2021-2026) & (Units)
Table 57. North America Furmonertinib Mesylate Sales Quantity by Country (2027-2032) & (Units)
Table 58. North America Furmonertinib Mesylate Consumption Value by Country (2021-2026) & (USD Million)
Table 59. North America Furmonertinib Mesylate Consumption Value by Country (2027-2032) & (USD Million)
Table 60. Europe Furmonertinib Mesylate Sales Quantity by Type (2021-2026) & (Units)
Table 61. Europe Furmonertinib Mesylate Sales Quantity by Type (2027-2032) & (Units)
Table 62. Europe Furmonertinib Mesylate Sales Quantity by Application (2021-2026) & (Units)
Table 63. Europe Furmonertinib Mesylate Sales Quantity by Application (2027-2032) & (Units)
Table 64. Europe Furmonertinib Mesylate Sales Quantity by Country (2021-2026) & (Units)
Table 65. Europe Furmonertinib Mesylate Sales Quantity by Country (2027-2032) & (Units)
Table 66. Europe Furmonertinib Mesylate Consumption Value by Country (2021-2026) & (USD Million)
Table 67. Europe Furmonertinib Mesylate Consumption Value by Country (2027-2032) & (USD Million)
Table 68. Asia-Pacific Furmonertinib Mesylate Sales Quantity by Type (2021-2026) & (Units)
Table 69. Asia-Pacific Furmonertinib Mesylate Sales Quantity by Type (2027-2032) & (Units)
Table 70. Asia-Pacific Furmonertinib Mesylate Sales Quantity by Application (2021-2026) & (Units)
Table 71. Asia-Pacific Furmonertinib Mesylate Sales Quantity by Application (2027-2032) & (Units)
Table 72. Asia-Pacific Furmonertinib Mesylate Sales Quantity by Region (2021-2026) & (Units)
Table 73. Asia-Pacific Furmonertinib Mesylate Sales Quantity by Region (2027-2032) & (Units)
Table 74. Asia-Pacific Furmonertinib Mesylate Consumption Value by Region (2021-2026) & (USD Million)
Table 75. Asia-Pacific Furmonertinib Mesylate Consumption Value by Region (2027-2032) & (USD Million)
Table 76. South America Furmonertinib Mesylate Sales Quantity by Type (2021-2026) & (Units)
Table 77. South America Furmonertinib Mesylate Sales Quantity by Type (2027-2032) & (Units)
Table 78. South America Furmonertinib Mesylate Sales Quantity by Application (2021-2026) & (Units)
Table 79. South America Furmonertinib Mesylate Sales Quantity by Application (2027-2032) & (Units)
Table 80. South America Furmonertinib Mesylate Sales Quantity by Country (2021-2026) & (Units)
Table 81. South America Furmonertinib Mesylate Sales Quantity by Country (2027-2032) & (Units)
Table 82. South America Furmonertinib Mesylate Consumption Value by Country (2021-2026) & (USD Million)
Table 83. South America Furmonertinib Mesylate Consumption Value by Country (2027-2032) & (USD Million)
Table 84. Middle East & Africa Furmonertinib Mesylate Sales Quantity by Type (2021-2026) & (Units)
Table 85. Middle East & Africa Furmonertinib Mesylate Sales Quantity by Type (2027-2032) & (Units)
Table 86. Middle East & Africa Furmonertinib Mesylate Sales Quantity by Application (2021-2026) & (Units)
Table 87. Middle East & Africa Furmonertinib Mesylate Sales Quantity by Application (2027-2032) & (Units)
Table 88. Middle East & Africa Furmonertinib Mesylate Sales Quantity by Country (2021-2026) & (Units)
Table 89. Middle East & Africa Furmonertinib Mesylate Sales Quantity by Country (2027-2032) & (Units)
Table 90. Middle East & Africa Furmonertinib Mesylate Consumption Value by Country (2021-2026) & (USD Million)
Table 91. Middle East & Africa Furmonertinib Mesylate Consumption Value by Country (2027-2032) & (USD Million)
Table 92. Furmonertinib Mesylate Raw Material
Table 93. Key Manufacturers of Furmonertinib Mesylate Raw Materials
Table 94. Furmonertinib Mesylate Typical Distributors
Table 95. Furmonertinib Mesylate Typical Customers
LIST OF FIGURES
Figure 1. Furmonertinib Mesylate Picture
Figure 2. Global Furmonertinib Mesylate Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Furmonertinib Mesylate Revenue Market Share by Type in 2025
Figure 4. 40 mg Examples
Figure 5. 80 mg Examples
Figure 6. Global Furmonertinib Mesylate Revenue by Sales Channels, (USD Million), 2021 & 2025 & 2032
Figure 7. Global Furmonertinib Mesylate Revenue Market Share by Sales Channels in 2025
Figure 8. Hospital Examples
Figure 9. Retail Examples
Figure 10. Online Examples
Figure 11.Tablets Examples
Figure 12. Powder Examples
Figure 13. Global Furmonertinib Mesylate Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 14. Global Furmonertinib Mesylate Revenue Market Share by Application in 2025
Figure 15. Non-small Cell Lung Cancer (NSCLC) Treatment Examples
Figure 16. Patients With Central Nervous System Metastases Examples
Figure 17. First-line and Later-line Targeted Therapy Examples
Figure 18. Others Examples
Figure 19. Global Furmonertinib Mesylate Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 20. Global Furmonertinib Mesylate Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 21. Global Furmonertinib Mesylate Sales Quantity (2021-2032) & (Units)
Figure 22. Global Furmonertinib Mesylate Price (2021-2032) & (US$/Unit)
Figure 23. Global Furmonertinib Mesylate Sales Quantity Market Share by Manufacturer in 2025
Figure 24. Global Furmonertinib Mesylate Revenue Market Share by Manufacturer in 2025
Figure 25. Producer Shipments of Furmonertinib Mesylate by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 26. Top 3 Furmonertinib Mesylate Manufacturer (Revenue) Market Share in 2025
Figure 27. Top 6 Furmonertinib Mesylate Manufacturer (Revenue) Market Share in 2025
Figure 28. Global Furmonertinib Mesylate Sales Quantity Market Share by Region (2021-2032)
Figure 29. Global Furmonertinib Mesylate Consumption Value Market Share by Region (2021-2032)
Figure 30. North America Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 31. Europe Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 32. Asia-Pacific Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 33. South America Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 34. Middle East & Africa Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 35. Global Furmonertinib Mesylate Sales Quantity Market Share by Type (2021-2032)
Figure 36. Global Furmonertinib Mesylate Consumption Value Market Share by Type (2021-2032)
Figure 37. Global Furmonertinib Mesylate Average Price by Type (2021-2032) & (US$/Unit)
Figure 38. Global Furmonertinib Mesylate Sales Quantity Market Share by Application (2021-2032)
Figure 39. Global Furmonertinib Mesylate Revenue Market Share by Application (2021-2032)
Figure 40. Global Furmonertinib Mesylate Average Price by Application (2021-2032) & (US$/Unit)
Figure 41. North America Furmonertinib Mesylate Sales Quantity Market Share by Type (2021-2032)
Figure 42. North America Furmonertinib Mesylate Sales Quantity Market Share by Application (2021-2032)
Figure 43. North America Furmonertinib Mesylate Sales Quantity Market Share by Country (2021-2032)
Figure 44. North America Furmonertinib Mesylate Consumption Value Market Share by Country (2021-2032)
Figure 45. United States Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 46. Canada Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 47. Mexico Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 48. Europe Furmonertinib Mesylate Sales Quantity Market Share by Type (2021-2032)
Figure 49. Europe Furmonertinib Mesylate Sales Quantity Market Share by Application (2021-2032)
Figure 50. Europe Furmonertinib Mesylate Sales Quantity Market Share by Country (2021-2032)
Figure 51. Europe Furmonertinib Mesylate Consumption Value Market Share by Country (2021-2032)
Figure 52. Germany Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 53. France Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 54. United Kingdom Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 55. Russia Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 56. Italy Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 57. Asia-Pacific Furmonertinib Mesylate Sales Quantity Market Share by Type (2021-2032)
Figure 58. Asia-Pacific Furmonertinib Mesylate Sales Quantity Market Share by Application (2021-2032)
Figure 59. Asia-Pacific Furmonertinib Mesylate Sales Quantity Market Share by Region (2021-2032)
Figure 60. Asia-Pacific Furmonertinib Mesylate Consumption Value Market Share by Region (2021-2032)
Figure 61. China Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 62. Japan Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 63. South Korea Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 64. India Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 65. Southeast Asia Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 66. Australia Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 67. South America Furmonertinib Mesylate Sales Quantity Market Share by Type (2021-2032)
Figure 68. South America Furmonertinib Mesylate Sales Quantity Market Share by Application (2021-2032)
Figure 69. South America Furmonertinib Mesylate Sales Quantity Market Share by Country (2021-2032)
Figure 70. South America Furmonertinib Mesylate Consumption Value Market Share by Country (2021-2032)
Figure 71. Brazil Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 72. Argentina Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 73. Middle East & Africa Furmonertinib Mesylate Sales Quantity Market Share by Type (2021-2032)
Figure 74. Middle East & Africa Furmonertinib Mesylate Sales Quantity Market Share by Application (2021-2032)
Figure 75. Middle East & Africa Furmonertinib Mesylate Sales Quantity Market Share by Country (2021-2032)
Figure 76. Middle East & Africa Furmonertinib Mesylate Consumption Value Market Share by Country (2021-2032)
Figure 77. Turkey Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 78. Egypt Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 79. Saudi Arabia Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 80. South Africa Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 81. Furmonertinib Mesylate Market Drivers
Figure 82. Furmonertinib Mesylate Market Restraints
Figure 83. Furmonertinib Mesylate Market Trends
Figure 84. Porters Five Forces Analysis
Figure 85. Manufacturing Cost Structure Analysis of Furmonertinib Mesylate in 2025
Figure 86. Manufacturing Process Analysis of Furmonertinib Mesylate
Figure 87. Furmonertinib Mesylate Industrial Chain
Figure 88. Sales Channel: Direct to End-User vs Distributors
Figure 89. Direct Channel Pros & Cons
Figure 90. Indirect Channel Pros & Cons
Figure 91. Methodology
Figure 92. Research Process and Data Source
Figure 1. Furmonertinib Mesylate Picture
Figure 2. Global Furmonertinib Mesylate Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Furmonertinib Mesylate Revenue Market Share by Type in 2025
Figure 4. 40 mg Examples
Figure 5. 80 mg Examples
Figure 6. Global Furmonertinib Mesylate Revenue by Sales Channels, (USD Million), 2021 & 2025 & 2032
Figure 7. Global Furmonertinib Mesylate Revenue Market Share by Sales Channels in 2025
Figure 8. Hospital Examples
Figure 9. Retail Examples
Figure 10. Online Examples
Figure 11.Tablets Examples
Figure 12. Powder Examples
Figure 13. Global Furmonertinib Mesylate Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 14. Global Furmonertinib Mesylate Revenue Market Share by Application in 2025
Figure 15. Non-small Cell Lung Cancer (NSCLC) Treatment Examples
Figure 16. Patients With Central Nervous System Metastases Examples
Figure 17. First-line and Later-line Targeted Therapy Examples
Figure 18. Others Examples
Figure 19. Global Furmonertinib Mesylate Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 20. Global Furmonertinib Mesylate Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 21. Global Furmonertinib Mesylate Sales Quantity (2021-2032) & (Units)
Figure 22. Global Furmonertinib Mesylate Price (2021-2032) & (US$/Unit)
Figure 23. Global Furmonertinib Mesylate Sales Quantity Market Share by Manufacturer in 2025
Figure 24. Global Furmonertinib Mesylate Revenue Market Share by Manufacturer in 2025
Figure 25. Producer Shipments of Furmonertinib Mesylate by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 26. Top 3 Furmonertinib Mesylate Manufacturer (Revenue) Market Share in 2025
Figure 27. Top 6 Furmonertinib Mesylate Manufacturer (Revenue) Market Share in 2025
Figure 28. Global Furmonertinib Mesylate Sales Quantity Market Share by Region (2021-2032)
Figure 29. Global Furmonertinib Mesylate Consumption Value Market Share by Region (2021-2032)
Figure 30. North America Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 31. Europe Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 32. Asia-Pacific Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 33. South America Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 34. Middle East & Africa Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 35. Global Furmonertinib Mesylate Sales Quantity Market Share by Type (2021-2032)
Figure 36. Global Furmonertinib Mesylate Consumption Value Market Share by Type (2021-2032)
Figure 37. Global Furmonertinib Mesylate Average Price by Type (2021-2032) & (US$/Unit)
Figure 38. Global Furmonertinib Mesylate Sales Quantity Market Share by Application (2021-2032)
Figure 39. Global Furmonertinib Mesylate Revenue Market Share by Application (2021-2032)
Figure 40. Global Furmonertinib Mesylate Average Price by Application (2021-2032) & (US$/Unit)
Figure 41. North America Furmonertinib Mesylate Sales Quantity Market Share by Type (2021-2032)
Figure 42. North America Furmonertinib Mesylate Sales Quantity Market Share by Application (2021-2032)
Figure 43. North America Furmonertinib Mesylate Sales Quantity Market Share by Country (2021-2032)
Figure 44. North America Furmonertinib Mesylate Consumption Value Market Share by Country (2021-2032)
Figure 45. United States Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 46. Canada Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 47. Mexico Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 48. Europe Furmonertinib Mesylate Sales Quantity Market Share by Type (2021-2032)
Figure 49. Europe Furmonertinib Mesylate Sales Quantity Market Share by Application (2021-2032)
Figure 50. Europe Furmonertinib Mesylate Sales Quantity Market Share by Country (2021-2032)
Figure 51. Europe Furmonertinib Mesylate Consumption Value Market Share by Country (2021-2032)
Figure 52. Germany Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 53. France Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 54. United Kingdom Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 55. Russia Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 56. Italy Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 57. Asia-Pacific Furmonertinib Mesylate Sales Quantity Market Share by Type (2021-2032)
Figure 58. Asia-Pacific Furmonertinib Mesylate Sales Quantity Market Share by Application (2021-2032)
Figure 59. Asia-Pacific Furmonertinib Mesylate Sales Quantity Market Share by Region (2021-2032)
Figure 60. Asia-Pacific Furmonertinib Mesylate Consumption Value Market Share by Region (2021-2032)
Figure 61. China Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 62. Japan Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 63. South Korea Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 64. India Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 65. Southeast Asia Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 66. Australia Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 67. South America Furmonertinib Mesylate Sales Quantity Market Share by Type (2021-2032)
Figure 68. South America Furmonertinib Mesylate Sales Quantity Market Share by Application (2021-2032)
Figure 69. South America Furmonertinib Mesylate Sales Quantity Market Share by Country (2021-2032)
Figure 70. South America Furmonertinib Mesylate Consumption Value Market Share by Country (2021-2032)
Figure 71. Brazil Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 72. Argentina Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 73. Middle East & Africa Furmonertinib Mesylate Sales Quantity Market Share by Type (2021-2032)
Figure 74. Middle East & Africa Furmonertinib Mesylate Sales Quantity Market Share by Application (2021-2032)
Figure 75. Middle East & Africa Furmonertinib Mesylate Sales Quantity Market Share by Country (2021-2032)
Figure 76. Middle East & Africa Furmonertinib Mesylate Consumption Value Market Share by Country (2021-2032)
Figure 77. Turkey Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 78. Egypt Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 79. Saudi Arabia Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 80. South Africa Furmonertinib Mesylate Consumption Value (2021-2032) & (USD Million)
Figure 81. Furmonertinib Mesylate Market Drivers
Figure 82. Furmonertinib Mesylate Market Restraints
Figure 83. Furmonertinib Mesylate Market Trends
Figure 84. Porters Five Forces Analysis
Figure 85. Manufacturing Cost Structure Analysis of Furmonertinib Mesylate in 2025
Figure 86. Manufacturing Process Analysis of Furmonertinib Mesylate
Figure 87. Furmonertinib Mesylate Industrial Chain
Figure 88. Sales Channel: Direct to End-User vs Distributors
Figure 89. Direct Channel Pros & Cons
Figure 90. Indirect Channel Pros & Cons
Figure 91. Methodology
Figure 92. Research Process and Data Source
